United Kingdom — National Health Service & Illumina — Holy Grail

United Kingdom — National Health Service: The NHS-Galleri trial, conducted in partnership with the UK's United Kingdom — National Health Service, failed to meet its primary endpoint. This outcome may affect the NHS's evaluation of the Galleri test for national screening programs, though the NHS itself is not a defendant in the lawsuits.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in multiple securities fraud class actions. The company's stock collapsed 50.55% after its NHS-Galleri trial failed to meet its primary endpoint, erasing over $2.2 billion in market capitalization. The litigation and trial failure severely damage its financial standing and investor trust.

United Kingdom — National Health Service: The NHS conducted the Galleri trial in the UK; the trial's failure may affect future collaboration with Illumina — Holy Grail.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in the securities class action; its stock dropped over 50% after the NHS-Galleri trial failed to meet its primary endpoint, resulting in a $2.2 billion market cap loss.